Nom du produit:azetidin-3-ol hydrochloride

IUPAC Name:azetidin-3-ol hydrochloride

CAS:18621-18-6
Formule moléculaire:C3H8ClNO
Pureté:95%+
Numéro de catalogue:CM102453
Poids moléculaire:109.55

Unité d'emballage Stock disponible Prix($) Quantité
CM102453-100g in stock Ʃƻ
CM102453-500g in stock ŭňƅ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:18621-18-6
Formule moléculaire:C3H8ClNO
Point de fusion:-
Code SMILES:Cl.OC1CNC1
Densité:
Numéro de catalogue:CM102453
Poids moléculaire:109.55
Point d'ébullition:
N° Mdl:MFCD02683887
Stockage:Store at room temperature.

Category Infos

Azetidines
Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.
Where to buy Azetidines
Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

Column Infos

Alicyclic Heterocycles
When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.
Povorcitinib
Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN). These data were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting.
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for PN.